NAGOYA, Japan, Aug. 23 - Menicon Company Ltd. announced on August 23 the appointment of Dr. Jennifer Choo as Manager of Specialty Lens Clinical Affairs for Menicon Holdings B.V. Dr. Choo will oversee the company's Rose K business while also handling professional and clinical affairs for the company's growing specialty lens portfolio.

For the last 3 years, Dr. Choo has been Project Leader at Adventus Technology
Inc. and the Brien Holden Vision Institute (BHVI) based in Sydney, Australia.
Dr. Choo has led and managed international and interdisciplinary teams in the
development of innovative surgical ophthalmic products. She previously served
as Project Director for Orthokeratology Research at BHVI while completing her
PhD.
Dr. Choo completed a Bachelor of Science in Cell Biology and Genetics from the
University of British Columbia in Vancouver. She obtained her Doctor of
Optometry from the Pacific University College of Optometry in Portland, Oregon,
and received her PhD in Vision Science from the University of New South Wales
in Sydney, Australia.
Dr. Choo has strong global experience as a lecturer and educator and is a
recipient of several research awards. She has also demonstrated outstanding
leadership skills while overseeing the development, production and evaluation
of novel ophthalmic devices. Dr. Choo will be based in Vancouver, Canada, and
will report to Mr. Jonathan Jacobson, Chief Executive Officer of Menicon
Holdings B.V.
"I am extremely excited to be joining the Menicon team," said Dr. Choo.
"Menicon is a diverse, dynamic and multinational company that continually works
to improve and innovate within the contact lens and lens care markets. I look
forward to working with the team and utilizing my skills and experiences to
help expand and establish the company's presence globally."
Mr. Jacobson commented: "We are thrilled to welcome Dr. Choo to Menicon. Her
considerable experience in clinical research and specialty lenses will be
invaluable to Menicon's global expansion plans, particularly during an active
period of new product introductions."